Diverse clinical applications using advantages of allogeneic peripheral blood stem cell transplantation.
The diverse clinical applications of allogeneic peripheral blood stem cells based on use of their advantages are summarized. It is apparent that more stem cells and T-lymphocytes can be harvested by mobilization treatment with cytokines from healthy donors in allogeneic peripheral blood stem cell transplantation (PBSCT) than in bone marrow transplantation. It is also clear that a stronger graft-versus-tumor effect can be induced with allogeneic PBSCT than with bone marrow transplantation. One merit of allogeneic PBSCT is that it allows clinicians to design diverse clinical applications. It would appear that allogeneic PBSCT may be preferable in special clinical settings, such as advanced hematological malignancies, situations requiring a strong graft-versus-tumor effect, nonmyeloablative stem cell transplantation, and situations requiring a megadose of stem cells. Cytokine-primed peripheral blood stem cells can also be used for adoptive immunotherapy, such as a nonprimed donor lymphocyte infusion.
Sohn
Sang Kyun
SK
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. sksohn@knu.ac.kr
Kim
Jong Gwang
JG
Kim
Dong Hwan
DH
Baek
Jin Ho
JH
Lee
Kyu Bo
KB
D016207:Cytokines / Q000627:therapeutic use; D020350:Graft vs Tumor Effect; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D017710:Lymphocyte Transfusion; D036102:Peripheral Blood Stem Cell Transplantation; D016019:Survival Analysis; D013601:T-Lymphocytes; D014184:Transplantation, Homologous
D016207:Cytokines